New digital PET/CT could spot hidden artery inflammation and prevent blindness
NCT ID NCT05000138
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
Giant cell arteritis (GCA) causes inflamed arteries and can lead to blindness if not treated quickly. This study tested a new digital PET/CT scan that can see tiny arteries in the head, which older scans missed. 92 patients with suspected GCA got both a PET/CT and an ultrasound. Researchers compared the scans to see if the new PET/CT could be a one-stop test for faster, more accurate diagnosis.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
FDG (radioactive glucose) injected for PET/CT scan
What this could lead to
If successful, digital PET/CT could become a single, reliable test to quickly diagnose giant cell arteritis, reducing the risk of blindness.
What could go wrong
This is a small, completed study (92 participants) comparing PET/CT to ultrasound. The new scan may not be accurate enough to replace current methods, and results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GIANT CELL ARTERITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHUS
Sherbrooke, Quebec, H3T1C5, Canada
-
Hôpital du Sacré-Cœur de Montréal
Montreal, Quebec, H4J 1C5, Canada
-
Jewish General Hospital
Montreal, Quebec, H4R3E8, Canada
-
University Medical Center Groningen
Groningen, Netherlands
-
Université Bourgogne Europe, Centre Georges-François Leclerc
Dijon, 21000, France